Does anemia affect outcome after lobectomy or pneumonectomy in early stage lung cancer patients who have not received neo-adjuvant treatment?

被引:19
|
作者
Chamogeorgakis, T. [1 ]
Anagnostopoulos, C. [1 ]
Kostopanagiotou, G. [2 ]
Bhora, F. [3 ]
Toumpoulis, I. [2 ]
Georglannakis, E. [2 ]
Nabong, A. [3 ]
Dosios, T. [2 ]
Harrison, L. [3 ]
Connery, C.
机构
[1] Attikon Univ Hosp, Dept Cardiothorac Surg, Voula 16673, Greece
[2] Attikon Univ Hosp, Dept Anesthesiol, Athens, Greece
[3] St Lukes & Roosevelt Hosp, Continuum Canc Ctr, Dept Cardiothorac Surg & Radiat Oncol, New York, NY USA
来源
THORACIC AND CARDIOVASCULAR SURGEON | 2008年 / 56卷 / 03期
关键词
anemia; non small cell lung cancer; neo-adjuvant treatment; survival;
D O I
10.1055/s-2007-989455
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Backround: Preoperative anemia has been shown to be an ominous prognostic factor for survival in patients with early stage non small cell lung cancer. Methods: Two hundred and fourteen patients underwent resection for early stage non small cell lung cancer between 2001 and 2006 without neo-adjuvant treatment. Patients were divided into four groups based on their admission hemoglobin (Hgb): group I: Hgb <= 12 g/dl, group II: Hgb = 12.1-12.9g/dl, group III: Hgb=13.0-14.0g/dl, and group IV: Hgb > 14 g/dl. Cox regression analysis was used to evaluate each variable's impact on midterm survival taking all causes and lung cancer-specific mortality into account. Kaplan-Meier survival plots were estimated. Results: Preoperative hemoglobin (HR = 1.44,95 % confidence intervals 1.08 - 1.94, p = 0.014) and pneumonectomy (HR=3.58, 95% confidence intervals 1.26 - 10.16, p = 0.017) were the only predictors of all-cause midterm mortality. Similarly, when only lung cancer-related mortality was considered, preoperative hemoglobin (HR = 1.81, 95 % confidence intervals 1.17-2.78, p=0.007) and pneumonectomy (HR = 6.89, 95 % confidence intervals 2.29 - 20.73, p = 0.001,) were independent predictors. Age, gender, pulmonary function test results, tumor stage, and histology did not influence survival. Conclusions: Preoperative anemia and the type of resection in early stage non small cell lung cancer have an impact on midterm survival and lung cancer-specific mortality.
引用
收藏
页码:148 / 153
页数:6
相关论文
共 50 条
  • [21] Analysis of prognostic factors for surgery after neo-adjuvant therapy for stage III non-small cell lung cancer
    Xuefeng Zhou
    Jianjun Wang
    Jiashun Wang
    Yongcheng Pan
    Jingsong Li
    Wendong Wang
    Feng Zhao
    [J]. Journal of Huazhong University of Science and Technology [Medical Sciences], 2008, 28 : 677 - 680
  • [22] Phase III trials of neo-adjuvant chemotherapy in Stage IIIA non-small cell lung cancer - does size matter?
    Krieger, Laurence
    Pavlakis, Nick
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2009, 5 (02) : 73 - 75
  • [23] Development of a Patient Decision Aid for Rectal Cancer Patients with Clinical Complete Response after Neo-Adjuvant Treatment
    Smets, Lien
    Debucquoy, Annelies
    Oldenburger, Eva
    Van Audenhove, Chantal
    Debrun, Lynn
    Dekervel, Jeroen
    Bislenghi, Gabriele
    D'Hoore, Andre
    Wolthuis, Albert
    Haustermans, Karin
    [J]. CANCERS, 2023, 15 (03)
  • [24] Survivorship in Early-Stage Rectal Cancer Patients Who Have Received Combined Modality Therapy
    Randhawa, Saboor E.
    Tenner, Laura
    [J]. CLINICAL COLORECTAL CANCER, 2023, 22 (04) : 375 - 382
  • [25] ADJUVANT CHEMOTHERAPY DOES NOT AFFECT EMPLOYMENT IN PATIENTS WITH EARLY-STAGE BREAST-CANCER
    BUSHUNOW, PW
    SUN, YQ
    RAUBERTAS, RF
    ROSENTHAL, S
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 1995, 10 (02) : 73 - 76
  • [26] Time to initiation of neo-adjuvant chemotherapy for breast cancer treatment does not influence patient survival: A study of US breast cancer patients
    Livingston-Rosanoff, Devon
    Hanlon, Bret
    Marka, Nicholas
    Vande Walle, Kara
    Stankowski-Drengler, Trista
    Schumacher, Jessica
    Greenberg, Caprice C.
    Neuman, Heather
    Wilke, Lee G.
    [J]. BREAST JOURNAL, 2020, 26 (04): : 625 - 629
  • [27] A pragmatic cluster-randomized trial of ambulatory toxicity management in patients receiving adjuvant or neo-adjuvant chemotherapy for early stage breast cancer (AToM)
    Krzyzanowska, M. K.
    Julian, J.
    Gu, C-S.
    Powis, M.
    Li, Q.
    Enright, K. A.
    Howell, D.
    Earle, C.
    Gandhi, S.
    Rask, S.
    Brezden-Masley, C.
    Dent, S. F.
    Hajra, L.
    Freedman, O.
    Spadafora, S.
    Hamm, C.
    Califaretti, N.
    Trudeau, M.
    Levine, M.
    Grunfeld, E.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S1214 - S1214
  • [28] Ambulatory Toxicity Management (AToM) in patients receiving adjuvant or neo-adjuvant chemotherapy for early stage breast cancer - a pragmatic cluster randomized trial protocol
    Monika K. Krzyzanowska
    Jim A. Julian
    Melanie Powis
    Doris Howell
    Craig C. Earle
    Katherine A. Enright
    Nicole Mittmann
    Maureen E. Trudeau
    Eva Grunfeld
    [J]. BMC Cancer, 19
  • [29] The prognostic role of tumor-infiltrating lymphocytes after treatment with neo-adjuvant chemotherapy in inflammatory breast cancer patients
    Van Berckelaer, Christophe
    Vercauteren, Leonie
    Vermeiren, Iris
    Broeckx, Glenn
    Van Laere, Steven
    Dirix, Luc
    Colpaert, Cecile
    Van Dam, Peter
    [J]. CANCER RESEARCH, 2021, 81 (04)
  • [30] The Importance of Sleeve Lobectomy after Induction Therapy for Patients with Stage IIIA-N2 Lung Cancer: The Avoidance of Pneumonectomy
    Cho, Jong Ho
    Choi, Yong Soo
    Kim, Jhingook
    Kim, Hong Kwan
    Zo, Jae Ill
    Shim, Young Mog
    Kim, Kwhanmien
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S336 - S336